Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0848 • ACR Convergence 2020
Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef Smolen⁴, Daniel Wallace⁵, Brenda Crowe⁶, Ernst Dow⁶, Richard Higgs⁶, Guilherme Rocha⁶, Robert Benschop⁶, Maria Silk⁶, Stephanie de Bono⁶, Robert Hoffman⁶ and Damiano Fantini⁶, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Given the unmet clinical needs in systemic lupus erythematosus (SLE), including poor disease control and drug toxicities, new therapies are needed. In a phase…
Abstract Number: 0866 • ACR Convergence 2020
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
Joan Merrill¹, Matthew Studham², Eric Morand³, Aida Aydemir², Cristina Vazquez Mateo², Alex Rolfe², Amy Kao² and Robert Townsend², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
Abstract Number: 0983 • ACR Convergence 2020
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Danae Papachristos¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known…
Abstract Number: 1026 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
Estefania Gauto-Mariotti¹, Soumyasri Kambhatla² and Augustine Manadan³, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²John H Stroger Hospital of Cook County, Riverside, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 1264 • ACR Convergence 2020
Mortality in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Frits Rosendaal¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Little is known about mortality in patients with systemic lupus erythematosus (SLE) presenting with neuropsychiatric (NP) symptoms. We aimed to evaluate all-cause and cause-specific…
Abstract Number: 1280 • ACR Convergence 2020
COVID-19 Infections May Increase the Risk of SLE Flares
Leila Khalili¹, Yevgeniya Gartshteyn², Nancyanne Schmidt³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵ and Anca Askanase³, ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ³Columbia University College of Physicians and Surgeons, New York, NY, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: COVID-19 has overwhelmed the healthcare systems in New York City. Initial data from the Columbia Lupus Cohort suggests that 4% of patients with systemic…
Abstract Number: 1296 • ACR Convergence 2020
Associations of Metabolic Syndrome and Adipokines in SLE
Diane Apostolopoulos¹, Fabien Vincent², Rachel Koelmeyer², Alberta Hoi¹ and Eric Morand³, ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Clayton, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Metabolic syndrome (MetS) is a chronic pro-inflammatory and pro-thrombotic state associated with increased atherosclerosis, cardiovascular events and type 2 diabetes. It is diagnosed in…
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
Abstract Number: 1626 • ACR Convergence 2020
Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience
Lara Sanchez-Bilbao¹, Marina De Cos-Gomez², Inigo Gonzalez-Mazon³, David Martinez-Lopez⁴, Juan Carlos Ruiz-San Millan², Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Approximately 10-20% of LN develop end stage renal disease (ESRD) and need…
Abstract Number: 1682 • ACR Convergence 2020
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Teresa Semalulu¹, Karen Beattie¹, Jeanine McColl¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner¹, Liane Heale², Mark Matsos¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³ACPAC - University of Toronto, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…
Abstract Number: 1794 • ACR Convergence 2020
Systemic Lupus Erythematosus and Geomagnetic Disturbances: A Time Series Analysis
George Stojan¹, Flavia Giammarino² and Michelle Petri³, ¹Johns Hopkins University, BALTIMORE, MD, ²Deutsche Bank, London, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: To examine the influence of solar cycle and geomagnetic effects on SLE disease activity.Methods: The data used for the analysis consisted of 327 observations…
Abstract Number: 1812 • ACR Convergence 2020
Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients
Cristina Lanata¹, Joanne Nititham², Kim Taylor², Sharon Chung², Laura Trupin¹, Patricia Katz³, Maria Dall'Era⁴, Jinoos Yazdany¹, Marina Sirota¹, Lisa Barcellos⁵ and Lindsey Criswell⁶, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵UC Berkeley, Berkeley, CA, ⁶Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Cross-sectional studies have shown associations between DNA methylation differences in whole blood with Systemic Lupus Erythematosus (SLE) status and outcomes such as lupus nephritis.…
Abstract Number: 1828 • ACR Convergence 2020
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Eric Morand¹, Richard Furie², Ian Bruce³, Ed Vital⁴, Maria Dall'Era⁵, Emmanuelle Maho⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Monash University, Melbourne, Australia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…
Abstract Number: 1846 • ACR Convergence 2020
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
Jacinta Renaldi¹, Fotios Koumpouras¹ and Mei Xue Dong¹, ¹YALE SCHOOL OF MEDICINE, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease predominantly affecting woman of child-bearing age. Concurrent fibromyalgia syndrome (FMS) has been reported in…
Abstract Number: 0249 • ACR Convergence 2020
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan² and Meenakshi Jolly³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Rush University, Chicago, IL
Background/Purpose: The SIMPLE (SIMple Disease Assessment for People with Lupus Erythematosus) index is a composite numeric tool that captures disease activity from patients’ self-assessment with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].